HC Wainwright Has Negative Forecast for SGMT FY2026 Earnings

Sagimet Biosciences Inc. (NASDAQ:SGMT – Free Report) – Equities researchers at HC Wainwright decreased their FY2026 earnings estimates for Sagimet Biosciences in a report released on Friday, November 13th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($1.52) for the year, down from their previous forecast of ($1.31). HC Wainwright has a “Buy” rating and a $29.00 price objective on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Sagimet Biosciences’ Q4 2026 earnings at ($0.36) EPS, FY2027 earnings at ($1.29) EPS, FY2028 earnings at ($0.88) EPS and FY2029 earnings at $0.72 EPS.

Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.05).

Several other equities research analysts also recently issued reports on SGMT. Citigroup reaffirmed a “market outperform” rating on shares of Sagimet Biosciences in a research note on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Sagimet Biosciences in a research report on Thursday, October 15th. Canaccord Genuity Group lowered their target price on Sagimet Biosciences from $56.00 to $50.00 and set a “buy” rating for the company in a research note on Friday. Barclays raised Sagimet Biosciences from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $8.00 to $18.00 in a research report on Wednesday, September 9th. Finally, Wall Street Zen cut Sagimet Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Sagimet Biosciences has a consensus rating of “Moderate Buy” and an average target price of $26.07.

Check Out Our Latest Report on SGMT

Sagimet Biosciences Trading Down 0.9%

Shares of SGMT stock opened at $10.13 on Tuesday. The company has a market capitalization of $629.68 million, a PE ratio of -8.51 and a beta of 3.43. The firm has a fifty day simple moving average of $9.86 and a 200-day simple moving average of $7.71. Sagimet Biosciences has a twelve month low of $4.50 and a twelve month high of $11.45.

Institutional Trading of Sagimet Biosciences

A number of hedge funds have recently made changes to their positions in SGMT. Marshall Wace LLP bought a new stake in shares of Sagimet Biosciences in the third quarter worth $7,433,000. Nantahala Capital Management LLC bought a new position in Sagimet Biosciences during the 3rd quarter valued at $4,662,000. Renaissance Technologies LLC boosted its stake in Sagimet Biosciences by 82.6% during the 1st quarter. Renaissance Technologies LLC now owns 625,469 shares of the company’s stock valued at $3,268,000 after acquiring an additional 282,969 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in Sagimet Biosciences during the 2nd quarter worth $3,119,000. Finally, AWM Investment Company Inc. grew its holdings in Sagimet Biosciences by 275.0% during the 3rd quarter. AWM Investment Company Inc. now owns 300,000 shares of the company’s stock worth $2,964,000 after acquiring an additional 220,000 shares in the last quarter. Institutional investors and hedge funds own 87.86% of the company’s stock.

Key Headlines Impacting Sagimet Biosciences

These are some of the SGMT headlines that stood out recently:

About Sagimet Biosciences

(Get Free Report)

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing medicines that target fatty acid synthase (FASN), an enzyme involved in the body’s production of fatty acids. The company is based in San Mateo, California. Its lead drug candidate, denifanstat (also known as TVB-2640), is an oral FASN inhibitor being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The candidate has also been studied for other conditions. Sagimet is also developing TVB-3567, another FASN inhibitor being investigated as a potential treatment for acne.

Read More

Earnings History and Estimates for Sagimet Biosciences (NASDAQ:SGMT)

Receive News & Ratings for Sagimet Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagimet Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.